Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M36,462Revenue $M2,234Net Margin (%)29.4Z-Score26.5
Enterprise Value $M34,665EPS $3.3Operating Margin %38.9F-Score8
P/E(ttm))55.3Cash Flow Per Share $0.8Pre-tax Margin (%)39.0Higher ROA y-yY
Price/Book10.810-y EBITDA Growth Rate %0Quick Ratio4.3Cash flow > EarningsN
Price/Sales16.35-y EBITDA Growth Rate %52.3Current Ratio4.6Lower Leverage y-yY
Price/Cash Flow115y-y EBITDA Growth Rate %63.8ROA % (ttm)17.9Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)22.8Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M202ROI % (ttm)16.0Gross Margin Increase y-yY

Gurus Latest Trades with ALXN

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALXNJoel Greenblatt 2014-12-31 Add0.13%$159.46 - $200.79
($185.68)
$ 180.37-3%Add 4665.74%85,974
ALXNRay Dalio 2014-12-31 Buy 0.03%$159.46 - $200.79
($185.54)
$ 180.37-3%New holding, 18513 sh.18,513
ALXNRon Baron 2014-12-31 Add$159.46 - $200.79
($185.68)
$ 180.37-3%Add 41.92%18,366
ALXNAndreas Halvorsen 2014-12-31 Reduce-1.23%$159.46 - $200.79
($185.68)
$ 180.37-3%Reduce -82.25%390,271
ALXNAndreas Halvorsen 2014-09-30 Add0.13%$155.06 - $173.08
($164.22)
$ 180.3710%Add 9.59%2,198,451
ALXNRon Baron 2014-09-30 Add$155.06 - $173.08
($164.22)
$ 180.3710%Add 27.56%12,941
ALXNJoel Greenblatt 2014-09-30 Reduce-0.03%$155.06 - $173.08
($164.22)
$ 180.3710%Reduce -89.45%1,804
ALXNRay Dalio 2014-09-30 Sold Out -0.03%$155.06 - $173.08
($164.22)
$ 180.3710%Sold Out0
ALXNAndreas Halvorsen 2014-06-30 Add0.12%$139.61 - $170.2
($157.93)
$ 180.3714%Add 9.23%2,006,092
ALXNJoel Greenblatt 2014-06-30 Add0.02%$139.61 - $170.2
($157.93)
$ 180.3714%Add 240.11%17,094
ALXNRay Dalio 2014-06-30 Reduce-0.03%$139.61 - $170.2
($157.93)
$ 180.3714%Reduce -47.72%26,332
ALXNJohn Burbank 2014-06-30 Sold Out -0.01%$139.61 - $170.2
($157.93)
$ 180.3714%Sold Out0
ALXNRay Dalio 2014-03-31 Buy 0.06%$129.82 - $183.89
($158.27)
$ 180.3714%New holding, 50371 sh.50,371
ALXNJohn Burbank 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 180.3714%New holding, 1318 sh.1,318
ALXNRon Baron 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 180.3714%New holding, 10218 sh.10,218
ALXNJoel Greenblatt 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 180.3714%New holding, 5026 sh.5,026
ALXNFrank Sands 2014-03-31 Reduce-0.74%$129.82 - $183.89
($158.27)
$ 180.3714%Reduce -28.52%5,268,418
ALXNAndreas Halvorsen 2014-03-31 Reduce-0.65%$129.82 - $183.89
($158.27)
$ 180.3714%Reduce -36.16%1,836,658
ALXNAndreas Halvorsen 2013-12-31 Reduce-0.37%$105.48 - $132.91
($119.84)
$ 180.3750%Reduce -16.72%2,877,008
ALXNAndreas Halvorsen 2013-09-30 Reduce-1.06%$94.34 - $117.28
($109.83)
$ 180.3764%Reduce -37.7%3,454,640
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALXN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ALXN Ray Dalio 2014-12-3118,5130.010.03New Buy
ALXN Joel Greenblatt 2014-12-3185,9740.040.13+4665.74%
ALXN Ron Baron 2014-12-3118,3660.010.01+41.92%
ALXN Frank Sands 2014-12-315,267,9032.612.3-0.82%
ALXN Andreas Halvorsen 2014-12-31390,2710.190.33-82.25%
Premium Most recent portfolio changes are included for Premium Members only!


ALXN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
O'Neill JulieEVP. Global Operations 2015-02-10Sell795$171.156.15view
Sinha VikasEVP & CFO 2015-02-10Sell1,985$171.156.15view
Monnet DominiqueSVP, Chief Marketing Officer 2015-02-10Sell325$171.156.15view
MACKAY MARTINEVP & Global Head of R&D 2015-02-10Sell3,897$173.974.43view
Moriarty John BEVP & General Counsel 2015-02-10Sell1,490$171.156.15view
Islam SaqibEVP, Chief Strat & Port. Off. 2015-02-10Sell1,500$171.156.15view
BELL LEONARDCEO 2015-02-10Sell5,740$171.156.15view
Hallal DavidCOO 2015-02-10Sell1,980$171.156.15view
Carmichael ClareEVP, Chief HR Officer 2015-02-10Sell1,490$171.156.15view
BELL LEONARDCEO 2015-02-09Sell8,660$173.984.43view

Press Releases about ALXN :

    Quarterly/Annual Reports about ALXN:

    News about ALXN:

    Articles On GuruFocus.com
    Alexion Pharma Downgraded Despite Progress in Pipeline Jan 05 2015 
    Weekly CFO Sells Highlight: Alexion Pharmaceuticals Inc, Equity Residential, Tableau Software Inc. Dec 08 2014 
    Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY Dec 08 2014 
    CEO of Alexion Pharmaceuticals Sells Company Stock Sep 29 2014 
    Alexion CEO Receives Nearly $17 Million for Sale of Company Stock Aug 14 2014 
    Weekly CFO Sells Highlight: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc., Therm Feb 10 2014 
    Weekly Insider Sells Highlight: EA, ALXN, AAL, TMO Feb 09 2014 
    You Can No Longer Ignore Biotech Feb 07 2014 
    Six High-Impact Sells - Viking Global Investors Aug 26 2013 
    CEO of Alexion Pharmaceuticals Inc. Leonard Bell Sold 140,000 Shares Aug 19 2013 

    More From Other Websites
    7:24 am Alexion Pharma receives CHMP positive opinions for updates to the EU Label for Soliris Feb 27 2015
    Alexion Receives CHMP Positive Opinions for Important Updates to the EU Label for Soliris®... Feb 27 2015
    Alexion Joins Patient Organizations Worldwide in Support of International Rare Disease Day 2015 Feb 27 2015
    Alexion to Present at Investor Conferences Feb 23 2015
    Alexion to Present at Investor Conferences Feb 23 2015
    ALEXION PHARMACEUTICALS INC Financials Feb 13 2015
    New Data from a Natural History Study in Patients with Infantile- and Juvenile-Onset... Feb 09 2015
    10-K for Alexion Pharmaceuticals, Inc. Feb 08 2015
    ALEXION PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Feb 06 2015
    Canada Wants Alexion to Repay Sales Generated by 'Excessive Pricing' Feb 06 2015
    Gilead, Amgen Q4 Earnings & Weak Outlook Affect Biotech ETFs - ETF News And Commentary Feb 06 2015
    Alexion to Present at the 2015 Leerink Global Healthcare Conference Feb 05 2015
    Alexion Pharmaceuticals (ALXN) Earnings Report: Q4 2014 Conference Call Transcript Feb 03 2015
    PRESS DIGEST-Canada-Feb 3 Feb 03 2015
    Qiagen (QGEN) Disappoints with Q4 Earnings, Revenue Miss - Analyst Blog Jan 30 2015
    Alexion Pharmaceuticals (ALXN) Jumps: Stock Rises 5.8% - Tale of the Tape Jan 30 2015
    Biogen, Alexion Earnings Top Views, Shares Jump Jan 29 2015
    Alexion Pharmaceuticals Names COO to CEO Jan 29 2015
    ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 29 2015
    Thursday's Market Recap Jan 29 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK